Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | SCN4A | P35499 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219411 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL219725 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL1282789 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL25424554 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL1682624 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL1707911 | 0.78 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL30720790 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL18038426 | 0.75 | CYP3A4 (0.50) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL222470 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR | |
| SCHEMBL27264665 | 0.74 | SCN4A (0.49) | SMN1; SMN2ALDH1A1CYP3A4TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| CN-103249732-B | The bacterial topoisomerase II of suppression 2-ethyl carbamyl amino-1,3-benzothiazole-5-base | 生物区欧洲有限公司 | 2016-08-10 | — | — | CN | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| EP-2828257-A1 | ANTIBACTERIAL COMPOUNDS | Biota Europe Ltd (GB) | 2015-01-28 | — | — | EP | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| EP-2034997-A1 | ANTIBACTERIAL COMPOSITIONS | Prolysis Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | STS, PGLS, PEPD | SMN1; SMN2 4614/4885ALDH1A1 2417/4885CYP3A4 90/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | SMN1; SMN2 3693/4885ALDH1A1 3469/4885CYP3A4 849/4885 |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | STS, PEPD, PGLS | SMN1; SMN2 4323/4885ALDH1A1 2684/4885CYP3A4 80/4885 |
| US-20110263590-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | SMN1; SMN2 3013/4885ALDH1A1 2924/4885CYP3A4 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.